MMP2 and renal cell carcinoma: In RCC, silibinin inhibits the invasion and migration of RCC 786-O cells in vitro, which is associated with suppressed expression of metalloproteinase (MMP)-2, -9, and urokinase plasminogen activator, and inhibition of mitogen-activated protein kinase (MAPK) pathway signaling [15].